Antisoma restructures, considers sale following AS1413 failure
This article was originally published in Scrip
Antisoma is considering all options to maximise shareholder value, including a possible sale of the company, as it picks up the pieces following the recent Phase III failure of lead development programme AS1413 in secondary acute myeloid leukaemia (AML) (scripintelligence.com, 31 January 2011).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.